Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...9596979899100101102103104105...136137»
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    [VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_2172;    
    The treatment regimen at the time of the HSCT was performed with Pyridostigmine 180mg/day, Prednisolone 25mg/day, Azathioprine 100mg/day, and Mycophenolate mofetil 500mg/day...The treatment lines between diagnosis and HSCT were Pyridostigmine 60mg every 6 hours, Prednisone 100mg/day, Azathioprine 50mg every 8 hours, Cyclophosphamide 1gr IV every month for 6 months, Immunoglobulin 2014 and 2016, Rituximab 375mg/m2 IV every 4 weeks and Plasmapheresis in acute exacerbations... Although information about survival in patients with a history of RMG undergoing HSCT is scarce, in these two cases we evidence a good response of both patients and a survival of 100% for both of them at the last follow-up. Clinical Trial Registry: No
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    [VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_2171;    
    The treatment regimen at the time of the HSCT was performed with Pyridostigmine 180mg/day, Prednisolone 25mg/day, Azathioprine 100mg/day, and Mycophenolate mofetil 500mg/day...The treatment lines between diagnosis and HSCT were Pyridostigmine 60mg every 6 hours, Prednisone 100mg/day, Azathioprine 50mg every 8 hours, Cyclophosphamide 1gr IV every month for 6 months, Immunoglobulin 2014 and 2016, Rituximab 375mg/m2 IV every 4 weeks and Plasmapheresis in acute exacerbations... Although information about survival in patients with a history of RMG undergoing HSCT is scarce, in these two cases we evidence a good response of both patients and a survival of 100% for both of them at the last follow-up. Clinical Trial Registry: No
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    [VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_2170;    
    The treatment regimen at the time of the HSCT was performed with Pyridostigmine 180mg/day, Prednisolone 25mg/day, Azathioprine 100mg/day, and Mycophenolate mofetil 500mg/day...The treatment lines between diagnosis and HSCT were Pyridostigmine 60mg every 6 hours, Prednisone 100mg/day, Azathioprine 50mg every 8 hours, Cyclophosphamide 1gr IV every month for 6 months, Immunoglobulin 2014 and 2016, Rituximab 375mg/m2 IV every 4 weeks and Plasmapheresis in acute exacerbations... Although information about survival in patients with a history of RMG undergoing HSCT is scarce, in these two cases we evidence a good response of both patients and a survival of 100% for both of them at the last follow-up. Clinical Trial Registry: No
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    [VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_2169;    
    The treatment regimen at the time of the HSCT was performed with Pyridostigmine 180mg/day, Prednisolone 25mg/day, Azathioprine 100mg/day, and Mycophenolate mofetil 500mg/day...The treatment lines between diagnosis and HSCT were Pyridostigmine 60mg every 6 hours, Prednisone 100mg/day, Azathioprine 50mg every 8 hours, Cyclophosphamide 1gr IV every month for 6 months, Immunoglobulin 2014 and 2016, Rituximab 375mg/m2 IV every 4 weeks and Plasmapheresis in acute exacerbations... Although information about survival in patients with a history of RMG undergoing HSCT is scarce, in these two cases we evidence a good response of both patients and a survival of 100% for both of them at the last follow-up. Clinical Trial Registry: No
  • ||||||||||  dexamethasone / Generic mfg.
    [VIRTUAL] Non-thymic, Atypical Carcinoid Tumor Presenting with Cushing's Syndrome in an Otherwise Healthy Young Male () -  Feb 4, 2021 - Abstract #AFMRER2021AFMR_ER_74;    
    Studies have suggested that when these tumors appear to be non-thymic in origin, they often express a more aggressive behavior and are associated with endocrinopathies. We presented a case of a young, healthy male who presented with nonspecific symptoms, but who had severe metabolic, immunologic, and orthopedic complications which can be explained by his excessive Cushingoid burden.
  • ||||||||||  Clinical, Retrospective data, Journal:  Clinical characteristics and outcome of pregnant patients with myasthenia gravis (Pubmed Central) -  Feb 4, 2021   
    The first and third trimesters of pregnancy are considered high-risk periods for MG exacerbations. Neonatal transient myasthenia is uncommon, but the newborn should be carefully monitored by obstetricians and neurologists.
  • ||||||||||  Review, Journal:  Monoclonal Antibodies as Neurological Therapeutics. (Pubmed Central) -  Feb 4, 2021   
    On the other hand, accumulating experience shows that monoclonal antibodies may carry class-specific and target-associated risks. This article provides an overview of different types of monoclonal antibodies and their characteristics and reviews monoclonal antibodies currently in use or under development for neurological disease.
  • ||||||||||  mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
    Trial completion, HEOR:  PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov) -  Feb 2, 2021   
    P=N/A,  N=167, Completed, 
    She tolerated killed vaccines but has not had live viral vaccines.  Conclusions Taking azathioprine with prednisone during pregnancy may cause secondary, reversible immune suppression in the fetus. Recruiting --> Completed
  • ||||||||||  pyridostigmine Bromide / Generic mfg.
    [VIRTUAL] The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_735;    
    Pyridostigmine bromide 60 mg/day, Methylprednisolone 20 mg/day were prescribed for 5 days...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Journal:  The Bedside Ice Pack Test for Myasthenia Gravis. (Pubmed Central) -  Feb 2, 2021   
    The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021. No abstract available
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  International consensus guidance for management of myasthenia gravis: 2020 update. (Pubmed Central) -  Feb 2, 2021   
    These results highlight the differences in quantitative features of AChR-specific CD4+ T cells and imply Th17-AChR-specific CD4 + T cells can serve as a biomarker in MG. This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for MG patients worldwide.
  • ||||||||||  Clinical, Journal:  Electrophysiological investigation for autonomic dysfunction in patients with myasthenia gravis: A prospective study. (Pubmed Central) -  Feb 2, 2021   
    As much as time went by after drug administration prolonged SSR latencies were obtained (p=0.043).Valsalva ratio was lower in the AchR antibody negative group (p=0.033). The findings showed that both ocular/generalized MG patients have a subclinical parasympathetic abnormality prominent in the AchR antibody negative group and pyridostigmine has a peripheral sympathetic cholinergic noncumulative effect.
  • ||||||||||  Journal:  Thymectomy and myasthenia gravis. (Pubmed Central) -  Jan 30, 2021   
    The findings showed that both ocular/generalized MG patients have a subclinical parasympathetic abnormality prominent in the AchR antibody negative group and pyridostigmine has a peripheral sympathetic cholinergic noncumulative effect. No abstract available
  • ||||||||||  Clinical, Journal:  Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report. (Pubmed Central) -  Jan 29, 2021   
    He responded well to intravenous immunoglobulin and was discharged with anticholinesterase inhibitors and long-term immunosuppression therapy. CONCLUSIONS This report demonstrates that when patients are admitted to the hospital with acute respiratory failure without any underlying pulmonary disease and with weakness of the respiratory muscles, the diagnosis of myasthenia gravis presenting with a myasthenic crisis should be considered.
  • ||||||||||  Review, Journal:  Complementopathies and precision medicine. (Pubmed Central) -  Jan 27, 2021   
    Recognizing that this field is rapidly expanding, we aim to provide a state-of-the-art review of (a) current understanding of complement biology for the clinician, (b) novel insights into complement with potential applicability to clinical practice, (c) complement in disease across various disciplines (hematology, nephrology, obstetrics, transplantation, rheumatology, and neurology), and (d) the potential future of precision medicine. Better understanding of complement diagnostics and therapeutics will not only facilitate physicians treating patients in clinical practice but also provide the basis for future research toward precision medicine in this field.
  • ||||||||||  Trial completion, Enrollment change:  Training for Diagnosing Neurological Disorders (clinicaltrials.gov) -  Jan 26, 2021   
    P=N/A,  N=241, Completed, 
    It is essential that patients with ICI-induced MG should be screened and monitored for myocarditis, a potentially fatal complication. Recruiting --> Completed | N=400 --> 241
  • ||||||||||  Journal:  Peripheral blood T lymphocytosis in thymoma: an insight into immunobiology. (Pubmed Central) -  Jan 26, 2021   
    Thymic intratumoral microenvironment might influence occurrence PBTL that may have a pathophysiologic link to development of autoimmune manifestations. Immunophenotypic characteristics of peripheral blood lymphoid cells should be the clue for accurate characterization and to avoid a misdiagnosis of a lymphoproliferative neoplasm.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
    Clinical, Review, Journal:  Update in immunosuppressive therapy of myasthenia gravis. (Pubmed Central) -  Jan 26, 2021   
    Treatment strategy in MG is quite challenging, mainly due to the disease heterogeneity in terms of clinical presentation, immunopathogenesis and drug response. To solve this dilemma, emerging treatment are based on biological drugs and use new targets of the immune pathway.
  • ||||||||||  Biomarker, Clinical, Journal:  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. (Pubmed Central) -  Jan 26, 2021   
    The persistence of thymus-associated B cells correlated with less favorable changes in clinical symptom measures, steroid dose required to manage symptoms, and marginal changes in AChR autoantibody titer. This investigation indicates that the diminished clinical response to thymectomy is related to persistent circulating thymus-associated B cell clones.
  • ||||||||||  prednisone / Generic mfg., mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
    Journal:  Ocular myasthenia gravis: updates on an elusive target. (Pubmed Central) -  Jan 23, 2021   
    Autoantibody testing increasingly provides valuable diagnostic and prognostic information. Despite these improvements, a lack of quality treatment trials creates significant challenges for evidence-based management guidelines.
  • ||||||||||  Journal:  Open versus thoracoscopic thymectomy for juvenile myasthenia gravis. (Pubmed Central) -  Jan 23, 2021   
    Thoracoscopic thymectomy in children is a safe and effective surgical technique for the treatment of JMG. Increased acceptance of this minimally invasive approach by children, families, and referring neurologists may enable earlier surgical intervention.
  • ||||||||||  Journal:  Myasthenia Gravis and Pregnancy. (Pubmed Central) -  Jan 23, 2021   
    We recommend 150 s as adequate ART between the PEF test and the next test when performing RNS in LEMS. No abstract available
  • ||||||||||  Zilbrysq (zilucoplan) / UCB
    Trial completion date, Trial primary completion date:  RAISE: Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Jan 22, 2021   
    P3,  N=130, Recruiting, 
    However, this review suggests that a multidisciplinary rehabilitation approach should be recommended to people with myasthenia gravis, and above all, for those with mild to moderate symptomatology. Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Jan 2021 --> May 2021
  • ||||||||||  pyridostigmine Bromide / Generic mfg.
    Clinical, Journal:  Administering Neostigmine as a Subcutaneous Infusion: A Case Report of a Patient Dying With Myasthenia Gravis. (Pubmed Central) -  Jan 21, 2021   
    Undertreated myasthenia gravis should therefore be considered as a potentially reversible cause of acute deterioration, especially in patients with complex comorbidities. The use of neostigmine as a continuous subcutaneous infusion may have a role in the management of such patients, particularly when enteral administration of acetylcholinesterase inhibitors is no longer possible.
  • ||||||||||  New trial:  MG-ETP: Education Program in Myasthenia (clinicaltrials.gov) -  Jan 18, 2021   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  Journal, Adverse events:  Ophthalmic adverse effects of lithium. (Pubmed Central) -  Jan 16, 2021   
    Additional studies are anticipated to be helpful in expanding the current understanding of lithium and its adverse ophthalmic side effects and certainly warranted to fill the knowledge gap. Close interprofessional management between psychiatrists and ophthalmologists is expected to be beneficial in patient care.